Phenylketonuria (PKU) is characterized by phenylalanine accumulation and progressive mental retardation caused by an unknown mechanism. We demonstrate that at pathological concentrations, phenylalanine self-assembles into fibrils with amyloid-like morphology and well-ordered electron diffraction. These assemblies are specifically recognized by antibodies, show cytotoxicity that can be neutralized by the antibodies and are present in the hippocampus of model mice and in parietal cortex brain tissue from individuals with PKU. This is, to our knowledge, the first demonstration that a single amino acid can form amyloid-like deposits, suggesting a new amyloidosis-like etiology for PKU.
At a glance
- Adult phenylketonuria. Am. J. Med. 117, 590–595 (2004).
- The neurochemistry of phenylketonuria. Eur. J. Pediatr. 159 (suppl.), S109–S113 (2000). &
- Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. J. Biol. Chem. 261, 6536–6541 (1986). &
- Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. J. Clin. Invest. 75, 40–48 (1985). et al.
- The reality of dietary compliance in the management of phenylketonuria. J. Inherit. Metab. Dis. 33, 665–670 (2010). , , &
- Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–366 (2006). &
- Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60–68 (2000). &
- Structure of core domain of fibril-forming PHF/Tau fragments. Biophys. J. 90, 1774–1789 (2006). , , &
- A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J. 16, 77–83 (2002).
- Structures for amyloid fibrils. FEBS J. 272, 5950–5961 (2005). &
- Global analysis of tandem aromatic octapeptide repeats: the significance of the aromatic-glycine motif. Bioinformatics 18, 880–883 (2002).
- Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J. Biol. Chem. 277, 35475–35480 (2002). , &
- Casting metal nanowires within discrete self-assembled peptide nanotubes. Science 300, 625–627 (2003). &
- Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545–8548 (1996). et al.
- β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4, 822–826 (1998).
- Phenylalanine reduces synaptic density in mixed cortical cultures from mice. Pediatr. Res. 59, 544–548 (2006). et al.
- Molecular basis for amyloid fibril formation and stability. Proc. Natl. Acad. Sci. USA 102, 315–320 (2005). , , , &
- CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545–1614 (2009). et al.
- FACTS: fast analytical continuum treatment of solvation. J. Comput. Chem. 29, 701–715 (2008). &
- A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006). et al.
- Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567–1576 (2009). et al.
- Mouse models of human phenylketonuria. Genetics 134, 1205–1210 (1993). , , &
- β-Phenylpyruvate induces long-term neurobehavioral damage and brain necrosis in neonatal mice. Behav. Brain Res. 143, 1–5 (2003). , , &
- Histological maturation of the neocortex in phenylketonuric rats. Early Hum. Dev. 8, 157–173 (1983). , , &
- Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002). , , , &
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507–511 (2002). et al.
- Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 16, 819–828 (2007).
- Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999). et al.
- Supplementary Text and Figures (2M)
Supplementary Methods and Supplementary Results